Prostate cancer cell‑derived spondin 2 boosts osteogenic factor levels in osteoblasts via the PI3K/AKT/mTOR pathway

Wang,Hongbo; Zhang,Ming; Lu,Wencheng; Yuan,Chao

doi:10.3892/or.2022.8460

Prostate cancer cell‑derived spondin 2 boosts osteogenic factor levels in osteoblasts via the PI3K/AKT/mTOR pathway

Authors:
- Hongbo Wang
- Ming Zhang
- Wencheng Lu
- Chao Yuan
View Affiliations

Affiliations: Department of Spinal Surgery, Zaozhuang Municipal Hospital, Zaozhuang, Shandong 277101, P.R. China
Published online on: December 9, 2022 https://doi.org/10.3892/or.2022.8460
Article Number: 23

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer is the leading cause of cancer death among men worldwide. Bone metastasis is one of the main problems arising from prostate cancer. Spondin 2 is a diagnostic marker specific for prostate cancer; however, the role of spondin 2 in prostate cancer‑driven osteogenesis remains unclear. The present study was carried out to explore the role of spondin 2 on prostate cancer cell‑induced osteogenesis. In the present study, the expression of spondin 2 was analyzed in prostate cancer samples obtained from Gene Expression Omnibus. The supernatant of prostate cancer cells was used to treat the osteoblast precursor MC3T3‑E1 cell line to determine the effect of spondin 2 on osteoblasts. The effect of spondin 2 on osteogenic factor production was also examined after neutralization with a spondin 2 antibody in vitro via reverse transcription‑quantitative PCR. Furthermore, the effect of spondin 2 on the PI3K/AKT/mTOR pathway was assessed using a patient dataset from The Cancer Genome Atlas and in vitro via western blot analysis. In addition, an inhibitor of spondin 2 receptor (ATN‑161) was used to explore the inhibition effect of spondin 2 receptor in MC3T3‑E1 cells. The results showed that spondin 2 promoted Osterix and Runx2 expression in osteoblasts, and this process was tightly associated with the activation of the PI3K/AKT/mTOR pathway. Moreover, it was demonstrated that the function of spondin 2 on prostate cancer‑driven osteogenesis at least partly relied on the integrin receptor α5β1. These results demonstrated that spondin 2 boosts osteogenesis via the PI3K/AKT/mTOR pathway under conditions of prostate tumor progression.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L and Chirgwin JM: Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 12:6213s–6216s. 2006. View Article : Google Scholar : PubMed/NCBI
3	Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, et al: EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: Treatment of relapsing and metastatic prostate cancer. Eur Urol. 79:263–282. 2021. View Article : Google Scholar : PubMed/NCBI
4	Clezardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F, Confavreux CB and Holen I: Bone metastasis: Mechanisms, therapies, and biomarkers. Physiol Rev. 101:797–855. 2021. View Article : Google Scholar : PubMed/NCBI
5	Dayyani F, Varkaris A, Araujo JC, Song JH, Chatterji T, Trudel GC, Logothetis CJ and Gallick GE: Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer. Prostate. 73:979–985. 2013. View Article : Google Scholar : PubMed/NCBI
6	Zhang C, Long F, Wan J, Hu Y and He H: MicroRNA-205 acts as a tumor suppressor in osteosarcoma via targeting RUNX2. Oncol Rep. 35:3275–3284. 2016. View Article : Google Scholar : PubMed/NCBI
7	Jagga S, Sharma AR, Kim EJ and Nam JS: Isoflavone-enriched whole soy milk powder stimulates osteoblast differentiation. J Food Sci Technol. 58:595–603. 2021. View Article : Google Scholar : PubMed/NCBI
8	Choi YH, Han Y, Jin SW, Lee GH, Kim GS, Lee DY, Chung YC, Lee KY and Jeong HG: Pseudoshikonin I enhances osteoblast differentiation by stimulating Runx2 and Osterix. J Cell Biochem. 119:748–757. 2018. View Article : Google Scholar : PubMed/NCBI
9	Li Y, Cao C, Jia W, Yu L, Mo M, Wang Q, Huang Y, Lim JM, Ishihara M, Wells L, et al: Structure of the F-spondin domain of mindin, an integrin ligand and pattern recognition molecule. EMBO J. 28:286–297. 2009. View Article : Google Scholar : PubMed/NCBI
10	Parry R, Schneider D, Hudson D, Parkes D, Xuan JA, Newton A, Toy P, Lin R, Harkins R, Alicke B, et al: Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer. Cancer Res. 65:8397–8405. 2005. View Article : Google Scholar : PubMed/NCBI
11	Qian X, Li C, Pang B, Xue M, Wang J and Zhou J: Spondin-2 (SPON2), a more prostate-cancer-specific diagnostic biomarker. PLoS One. 7:e372252012. View Article : Google Scholar : PubMed/NCBI
12	Zhang Q, Wang XQ, Wang J, Cui SJ, Lou XM, Yan B, Qiao J, Jiang YH, Zhang LJ, Yang PY and Liu F: Upregulation of spondin-2 predicts poor survival of colorectal carcinoma patients. Oncotarget. 6:15095–15110. 2015. View Article : Google Scholar : PubMed/NCBI
13	Feng Y, Hu Y, Mao Q, Guo Y, Liu Y, Xue W and Cheng S: Upregulation of spondin-2 protein expression correlates with poor prognosis in hepatocellular carcinoma. J Int Med Res. 47:569–579. 2019. View Article : Google Scholar : PubMed/NCBI
14	Schmid F, Wang Q, Huska MR, Andrade-Navarro MA, Lemm M, Fichtner I, Dahlmann M, Kobelt D, Walther W, Smith J, et al: SPON2, a newly identified target gene of MACC1, drives colorectal cancer metastasis in mice and is prognostic for colorectal cancer patient survival. Oncogene. 35:5942–5952. 2016. View Article : Google Scholar : PubMed/NCBI
15	Huang C, Ou R, Chen X, Zhang Y, Li J, Liang Y, Zhu X, Liu L, Li M, Lin D, et al: Tumor cell-derived SPON2 promotes M2-polarized tumor-associated macrophage infiltration and cancer progression by activating PYK2 in CRC. J Exp Clin Cancer Res. 40:3042021. View Article : Google Scholar : PubMed/NCBI
16	Yang RS, Lin WL, Chen YZ, Tang CH, Huang TH, Lu BY and Fu WM: Regulation by ultrasound treatment on the integrin expression and differentiation of osteoblasts. Bone. 36:276–283. 2005. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Ylitalo EB, Thysell E, Jernberg E, Lundholm M, Crnalic S, Egevad L, Stattin P, Widmark A, Bergh A and Wikström P: Subgroups of castration-resistant prostate cancer bone metastases defined through an inverse relationship between androgen receptor activity and immune response. Eur Urol. 71:776–787. 2017. View Article : Google Scholar : PubMed/NCBI
19	Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
20	Vo BT, Morton D Jr, Komaragiri S, Millena AC, Leath C and Khan SA: TGF-β effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway. Endocrinology. 154:1768–1779. 2013. View Article : Google Scholar : PubMed/NCBI
21	Tan M, Xu J, Siddiqui J, Feng F and Sun Y: Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis. Mol Cancer. 15:812016. View Article : Google Scholar : PubMed/NCBI
22	Zhang YL, Li Q, Yang XM, Fang F, Li J, Wang YH, Yang Q, Zhu L, Nie HZ, Zhang XL, et al: SPON2 Promotes M1-like macrophage recruitment and inhibits hepatocellular carcinoma metastasis by distinct integrin-Rho GTPase-hippo pathways. Cancer Res. 78:2305–2317. 2018. View Article : Google Scholar : PubMed/NCBI
23	Jiang W, Takeshita N, Maeda T, Sogi C, Oyanagi T, Kimura S, Yoshida M, Sasaki K, Ito A and Takano-Yamamoto T: Connective tissue growth factor promotes chemotaxis of preosteoblasts through integrin α5 and Ras during tensile force-induced intramembranous osteogenesis. Sci Rep. 11:23682021. View Article : Google Scholar : PubMed/NCBI
24	Bai G, Cai Z, Zhai X, Xiong J, Zhang F and Li H: A new nomogram for the prediction of bone metastasis in patients with prostate cancer. J Int Med Res. 49:30006052110583642021. View Article : Google Scholar : PubMed/NCBI
25	Lee Y, Schwarz E, Davies M, Jo M, Gates J, Wu J, Zhang X and Lieberman JR: Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J Orthop Res. 21:62–72. 2003. View Article : Google Scholar : PubMed/NCBI
26	Boucher J, Balandre AC, Debant M, Vix J, Harnois T, Bourmeyster N, Péraudeau E, Chépied A, Clarhaut J, Debiais F, et al: Cx43 present at the leading edge membrane governs promigratory effects of osteoblast-conditioned medium on human prostate cancer cells in the context of bone metastasis. Cancers (Basel). 12:30132020. View Article : Google Scholar : PubMed/NCBI
27	Rubin J, Fan X, Rahnert J, Sen B, Hsieh CL, Murphy TC, Nanes MS, Horton LG, Beamer WG and Rosen CJ: IGF-I secretion by prostate carcinoma cells does not alter tumor-bone cell interactions in vitro or in vivo. Prostate. 66:789–800. 2006. View Article : Google Scholar : PubMed/NCBI
28	Tucci M, Mosca A, Lamanna G, Porpiglia F, Terzolo M, Vana F, Cracco C, Russo L, Gorzegno G, Tampellini M, et al: Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease. Prostate Cancer Prostatic Dis. 12:94–99. 2009. View Article : Google Scholar : PubMed/NCBI
29	Marie PJ: Targeting integrins to promote bone formation and repair. Nat Rev Endocrinol. 9:288–295. 2013. View Article : Google Scholar : PubMed/NCBI
30	Xu X, Zhang C, Trotter TN, Gowda PS, Lu Y, Ponnazhagan S, Javed A, Li J and Yang Y: Runx2 deficiency in osteoblasts promotes myeloma progression by altering the bone microenvironment at new bone sites. Cancer Res. 80:1036–1048. 2020. View Article : Google Scholar : PubMed/NCBI
31	Liu Q, Li M, Wang S, Xiao Z, Xiong Y and Wang G: Recent advances of osterix transcription factor in osteoblast differentiation and bone formation. Front Cell Dev Biol. 8:6012242020. View Article : Google Scholar : PubMed/NCBI
32	Yuan G, Lian Z, Liu Q, Lin X, Xie D, Song F, Wang X, Shao S, Zhou B, Li C, et al: Phosphatidyl inositol 3-kinase (PI3K)-mTOR inhibitor PKI-402 inhibits breast cancer induced osteolysis. Cancer Lett. 443:135–144. 2019. View Article : Google Scholar : PubMed/NCBI
33	Zhu WB, Xiao N and Liu XJ: Dietary flavonoid tangeretin induces reprogramming of epithelial to mesenchymal transition in prostate cancer cells by targeting the PI3K/Akt/mTOR signaling pathway. Oncol Lett. 15:433–440. 2018.PubMed/NCBI
34	Le B, Powers GL, Tam YT, Schumacher N, Malinowski RL, Steinke L, Kwon G and Marker PC: Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer. PLoS One. 12:e01746582017. View Article : Google Scholar : PubMed/NCBI
35	LoRusso PM: Inhibition of the PI3K/AKT/mTOR pathway in solid tumors. J Clin Oncol. 34:3803–3815. 2016. View Article : Google Scholar : PubMed/NCBI
36	Liu H, Li X, Lin J and Lin M: Morroniside promotes the osteogenesis by activating PI3K/Akt/mTOR signaling. Biosci Biotechnol Biochem. 85:332–339. 2021. View Article : Google Scholar : PubMed/NCBI
37	Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, Kearsley JH and Li Y: PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death Dis. 5:e14372014. View Article : Google Scholar : PubMed/NCBI
38	Berrak O, Arisan ED, Obakan-Yerlikaya P, Coker-Gürkan A and Palavan-Unsal N: mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells. Apoptosis. 21:1158–1178. 2016. View Article : Google Scholar : PubMed/NCBI